title: Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution.
abstract: OBJECTIVE
  To review a single institution's long-term results with doxorubicin-based preoperative chemotherapy for American Joint Committee on Cancer (AJCC) stage IIIB extremity soft tissue sarcoma (STS).
  
  
  METHODS
  The records of all patients with AJCC stage IIIB extremity STS treated with preoperative chemotherapy between 1986 and 1990 at The University of Texas M.D. Anderson Cancer Center were reviewed to assess rates of response, local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS).
  
  
  RESULTS
  Seventy-six patients with stage IIIB disease received preoperative chemotherapy. The median sarcoma size was 10 cm. Seventy-two patients (95%) had tumors located deep to the muscular fascia. Most patients received a median of three preoperative cycles of doxorubicin and dacarbazine (ADIC), cyclophosphamide and ADIC (CyADIC), or other doxorubicin-based regimens. Radiographic response rates were as follows: complete response (CR), 9%; partial response (PR), 19%; minor response, 13%; stable disease, 30%; and progression, 30%. The overall objective major response rate (CRs plus PRs) was 27%. At a median follow-up time of 85 months, 5-year actuarial rates of LRFS, DMFS, DFS, and OS with 95% confidence intervals (CIs) were 83% (CI, 73% to 94%), 52% (CI, 41% to 66%), 46% (CI, 35% to 60%), and 59% (CI, 48% to 72%), respectively. Comparison of responding patients (CRs plus PRs) and nonresponding patients did not show any significant differences in LRFS, DMFS, DFS, or OS.
  
  
  CONCLUSIONS
  Preoperative doxorubicin-based chemotherapy was associated with response, DFS, and OS rates similar to those observed in randomized postoperative chemotherapy trials. Responding patients had rates of LRFS, DMFS, DFS, and OS comparable to those of nonresponders.
authors.affiliation: Sarcoma Center, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4195, USA. peter_pisters@surg.mdacc.tmc.edu
authors.forename: P W
authors.initials: PW
authors.lastname: Pisters
authors.forename: S R
authors.initials: SR
authors.lastname: Patel
authors.forename: D G
authors.initials: DG
authors.lastname: Varma
authors.forename: S C
authors.initials: SC
authors.lastname: Cheng
authors.forename: N P
authors.initials: NP
authors.lastname: Chen
authors.forename: H T
authors.initials: HT
authors.lastname: Nguyen
authors.forename: B W
authors.initials: BW
authors.lastname: Feig
authors.forename: A
authors.initials: A
authors.lastname: Pollack
authors.forename: R E
authors.initials: RE
authors.lastname: Pollock
authors.forename: R S
authors.initials: RS
authors.lastname: Benjamin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001132:Arm; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007866:Leg; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011300:Preoperative Care; D012509:Sarcoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin